Australia Adds Alzheimer’s Drug Patch To Coverage Formulary
This article was originally published in PharmAsia News
Australian authorities have decided to add the skin patch for delivering an Alzheimer's disease drug to the formulary covered under the national health plan, beginning next month. The Pfizer patch, considered to have fewer side effects than Aricept (donepezil) in tablet form, joins several other Alzheimer's drugs on the Pharmaceutical Benefits Scheme list. The drug does not cure the disease, but improves a patient's ability to function with it. (Click here for more
You may also be interested in...
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.